Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00015054 · ClinicalTrials.gov registry record · Phase 2

Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3

A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT00015054 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00015054, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to participate in a subsequent anticipated controlled trial of MPD (recruitment and execution), and to gather preliminary data on the ability of sweat patches to detect episodes of cocaine use.

Interventions

  • DRUG Methylphenidate

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 1998-09
Est. Completion 1999-11
Phase Phase 2

What the Registry Record Tells You About NCT00015054

The ClinicalTrials.gov registry entry for NCT00015054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Methylphenidate is the first listed.

NCT00015054 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00015054 about?

NCT00015054 is a clinical study titled "Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3". The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to partici...

What is the current status of trial NCT00015054?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 1998-09. Estimated completion is 1999-11.

What interventions are being tested in trial NCT00015054?

The interventions under investigation include: Methylphenidate (DRUG).

Who is sponsoring clinical trial NCT00015054?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.